Citi Upgrades Watson Pharmaceuticals (WPI) to Buy
More News related to WPI
- Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
- Watson Pharma (WPI) to License Ulipristal Acetate with HRA Pharma
- Watson and HRA Pharma Announce Exclusive Licensing Agreement to Commercialize Novel Emergency Contraceptive in the U.S.
- Watson Completes Acquisition of Eden Biodesign
- Needham & Co Downgrades Watson Pharmaceuticals (WPI) to Underperform.
More News related to Upgrades
- Fitch Raises Int'l Rectifier (IRF) Outlook from Negative to Stable
- DA Davidson Upgrades Vulcan Materials (VMC) to Neutral
- Citi Upgrades Developers Diversified Realty (DDR) to Hold
- Stifel Nicolaus Upgrades Cognizant Technology (CTSH) to Buy
- UBS Upgrades Commerce Bancshares (CBSH) to Buy; Valuation: Quality Deserves a Premium
Citi upgrades Watson Pharmaceuticals (NYSE: WPI) from Hold to Buy. Price target increased from $39 to $48.
Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, marketing, sale, and distribution of generic and brand pharmaceutical products primarily in the United States.
To see all the upgrades/downgrades on shares of WPI, visit our Analyst Ratings page.
Related Categories
UpgradesStocks Mentioned
-0.56Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
